These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38949880)

  • 1. Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
    Mayne KJ; Sardell RJ; Staplin N; Judge PK; Zhu D; Sammons E; Cherney DZ; Cheung AK; Maggioni AP; Nangaku M; Rossello X; Tuttle KR; Ihara K; Iwata T; Wanner C; Emberson J; Preiss D; Landray MJ; Baigent FMedSci C; Haynes R; Herrington WG;
    Clin J Am Soc Nephrol; 2024 Jul; 19(9):1119-29. PubMed ID: 38949880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
    Mayne KJ; Sardell RJ; Staplin N; Judge PK; Zhu D; Sammons E; Cherney DZI; Green JB; Levin A; Pontremoli R; Hauske SJ; Emberson J; Preiss D; Landray MJ; Baigent C; Wanner C; Haynes R; Herrington WG;
    Nephrol Dial Transplant; 2024 Sep; ():. PubMed ID: 39277784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):51-60. PubMed ID: 38061372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
    Wanner C; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; George JT; von Eynatten M; Hauske SJ;
    Diabetes Obes Metab; 2020 Dec; 22(12):2335-2347. PubMed ID: 32744354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin in Patients with Chronic Kidney Disease.
    ; Herrington WG; Staplin N; Wanner C; Green JB; Hauske SJ; Emberson JR; Preiss D; Judge P; Mayne KJ; Ng SYA; Sammons E; Zhu D; Hill M; Stevens W; Wallendszus K; Brenner S; Cheung AK; Liu ZH; Li J; Hooi LS; Liu W; Kadowaki T; Nangaku M; Levin A; Cherney D; Maggioni AP; Pontremoli R; Deo R; Goto S; Rossello X; Tuttle KR; Steubl D; Petrini M; Massey D; Eilbracht J; Brueckmann M; Landray MJ; Baigent C; Haynes R
    N Engl J Med; 2023 Jan; 388(2):117-127. PubMed ID: 36331190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
    Nangaku M; Herrington WG; Goto S; Maruyama S; Kashihara N; Ueki K; Wada J; Watada H; Nakashima E; Lee R; Massey D; Mayne KJ; Tomita A; Haynes R; Hauske SJ; Kadowaki T
    Clin Exp Nephrol; 2024 Jun; 28(6):588-595. PubMed ID: 38643286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.
    Sharma A; Ferreira JP; Zannad F; Pocock SJ; Filippatos G; Pfarr E; Petrini M; Kraus BJ; Wanner C; Packer M; Butler J; Anker SD
    Eur J Heart Fail; 2023 Aug; 25(8):1337-1348. PubMed ID: 37062851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
    Hadjadj S; Cooper ME; Steubl D; Petrini M; Hantel S; Mattheus M; Wanner C; Thomas MC
    Kidney Med; 2024 Mar; 6(3):100783. PubMed ID: 38419787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
    Fernández-Fernandez B; Sarafidis P; Soler MJ; Ortiz A
    Clin Kidney J; 2023 Aug; 16(8):1187-1198. PubMed ID: 37529652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
    Kraus BJ; Weir MR; Bakris GL; Mattheus M; Cherney DZI; Sattar N; Heerspink HJL; Ritter I; von Eynatten M; Zinman B; Inzucchi SE; Wanner C; Koitka-Weber A
    Kidney Int; 2021 Mar; 99(3):750-762. PubMed ID: 33181154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
    Mayne KJ; Staplin N; Keane DF; Wanner C; Brenner S; Cejka V; Stegbauer J; Judge PK; Preiss D; Emberson J; Trinca D; Dayanandan R; Lee R; Nolan J; Omata A; Green JB; Cherney DZI; Hooi LS; Pontremoli R; Tuttle KR; Lees JS; Mark PB; Davies SJ; Hauske SJ; Steubl D; Brückmann M; Landray MJ; Baigent C; Haynes R; Herrington WG;
    J Am Soc Nephrol; 2024 Feb; 35(2):202-215. PubMed ID: 38082486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
    J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
    Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
    JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.